On April 7, 2021 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”)
whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property ( “License IP”) for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021.
RGBP Security Details Share Structure Market Value1...........$80,550,759 a/o Apr 09, 2021 Authorized Shares...4,800,000,000 a/o Mar 31, 2021 Outstanding Shares..2,934,453,890 a/o Mar 31, 2021 Restricted................150,366,969 a/o Mar 31, 2021 Unrestricted............2,784,086,921 a/o Mar 31, 2021 Held at DTC.............2,722,831,147 a/o Mar 31, 2021 Float........213,897,122 a/o Feb 11, 2019 No Par Value
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.